Last reviewed · How we verify
Fispemifene once daily for 4 weeks
Fispemifene once daily for 4 weeks is a Small molecule drug developed by QuatRx Pharmaceuticals Company. It is currently in Phase 2 development.
At a glance
| Generic name | Fispemifene once daily for 4 weeks |
|---|---|
| Sponsor | QuatRx Pharmaceuticals Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy (PHASE2)
- A Preliminary Clinical Study to Evaluate Fispemifene in the Treatment of Hypogonadism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fispemifene once daily for 4 weeks CI brief — competitive landscape report
- Fispemifene once daily for 4 weeks updates RSS · CI watch RSS
- QuatRx Pharmaceuticals Company portfolio CI
Frequently asked questions about Fispemifene once daily for 4 weeks
What is Fispemifene once daily for 4 weeks?
Fispemifene once daily for 4 weeks is a Small molecule drug developed by QuatRx Pharmaceuticals Company.
Who makes Fispemifene once daily for 4 weeks?
Fispemifene once daily for 4 weeks is developed by QuatRx Pharmaceuticals Company (see full QuatRx Pharmaceuticals Company pipeline at /company/quatrx-pharmaceuticals-company).
What development phase is Fispemifene once daily for 4 weeks in?
Fispemifene once daily for 4 weeks is in Phase 2.